Intech Investment Management LLC grew its holdings in Edwards Lifesciences Corporation (NYSE:EW – Free Report) by 123.9% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 192,699 shares of the medical research company’s stock after acquiring an additional 106,642 shares during the period. Intech Investment Management LLC’s holdings in Edwards Lifesciences were worth $16,634,000 as of its most recent SEC filing.
Other large investors also recently added to or reduced their stakes in the company. Thoroughbred Financial Services LLC increased its stake in shares of Edwards Lifesciences by 22.4% during the 3rd quarter. Thoroughbred Financial Services LLC now owns 6,297 shares of the medical research company’s stock worth $543,000 after purchasing an additional 1,153 shares during the last quarter. Bessemer Group Inc. raised its holdings in shares of Edwards Lifesciences by 0.4% during the 3rd quarter. Bessemer Group Inc. now owns 28,358 shares of the medical research company’s stock valued at $2,447,000 after purchasing an additional 114 shares in the last quarter. Hantz Financial Services Inc. raised its holdings in shares of Edwards Lifesciences by 53.5% during the 3rd quarter. Hantz Financial Services Inc. now owns 2,745 shares of the medical research company’s stock valued at $237,000 after purchasing an additional 957 shares in the last quarter. IFG Advisory LLC lifted its stake in shares of Edwards Lifesciences by 14.1% in the 3rd quarter. IFG Advisory LLC now owns 7,586 shares of the medical research company’s stock valued at $655,000 after purchasing an additional 938 shares during the last quarter. Finally, Optas LLC lifted its stake in shares of Edwards Lifesciences by 8.5% in the 3rd quarter. Optas LLC now owns 2,457 shares of the medical research company’s stock valued at $212,000 after purchasing an additional 192 shares during the last quarter. 79.46% of the stock is owned by institutional investors.
Insider Activity
In related news, VP Daniel J. Lippis sold 619 shares of the business’s stock in a transaction dated Tuesday, November 10th. The stock was sold at an average price of $104.25, for a total transaction of $64,530.75. Following the completion of the transaction, the vice president owned 40,034 shares of the company’s stock, valued at approximately $4,173,544.50. The trade was a 1.52% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Donald E. Bobo, Jr. sold 48,900 shares of the business’s stock in a transaction dated Monday, November 9th. The stock was sold at an average price of $103.05, for a total value of $5,039,145.00. Following the transaction, the vice president directly owned 22,798 shares of the company’s stock, valued at $2,349,333.90. This represents a 68.20% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 53,945 shares of company stock valued at $5,498,306 over the last three months. 0.31% of the stock is currently owned by insiders.
Analysts Set New Price Targets
EW has been the topic of several analyst reports. Piper Sandler reissued an “overweight” rating and set a $115.00 target price (up from $101.00) on shares of Edwards Lifesciences in a research report on Thursday, November 5th. Wells Fargo & Company restated an “overweight” rating and set a $113.00 target price (up from $100.00) on shares of Edwards Lifesciences in a report on Thursday, November 5th. Leerink Partners boosted their price target on Edwards Lifesciences from $101.00 to $112.00 and gave the stock an “outperform” rating in a research report on Thursday, November 5th. Royal Bank Of Canada upped their price target on Edwards Lifesciences from $110.00 to $115.00 and gave the stock an “outperform” rating in a research note on Thursday, November 5th. Finally, Deutsche Bank set a $104.00 price target on Edwards Lifesciences in a research note on Tuesday, October 27th. Twenty-three analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $109.56.
Edwards Lifesciences Price Performance
Shares of Edwards Lifesciences stock opened at $107.16 on Monday. The firm has a fifty day simple moving average of $90.42 and a 200-day simple moving average of $86.32. The company has a current ratio of 4.60, a quick ratio of 3.86 and a debt-to-equity ratio of 0.05. Edwards Lifesciences Corporation has a 1-year low of $74.66 and a 1-year high of $107.69. The stock has a market capitalization of $61.62 billion, a price-to-earnings ratio of 60.54, a PEG ratio of 2.86 and a beta of 0.85.
Edwards Lifesciences (NYSE:EW – Get Free Report) last posted its earnings results on Wednesday, November 4th. The medical research company reported $0.80 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.74 by $0.06. The business had revenue of $1.72 billion for the quarter, compared to analyst estimates of $1.68 billion. Edwards Lifesciences had a net margin of 15.30% and a return on equity of 16.06%. Edwards Lifesciences’s revenue was up 10.5% compared to the same quarter last year. During the same period last year, the business posted $0.67 EPS. On average, sell-side analysts expect that Edwards Lifesciences Corporation will post 3.01 earnings per share for the current year.
Edwards Lifesciences Profile
Edwards Lifesciences is a medical technology company focused on therapies for structural heart disease and critical care. Its products include transcatheter and surgical heart valves, as well as technologies used to monitor patients during intensive care and surgery. The company traces its origins to 1958, when engineer Lowell Edwards and surgeon Albert Starr began developing an artificial heart valve. Their work led to the Starr-Edwards valve, introduced in 1960. Edwards Lifesciences is headquartered in Irvine, California, and serves clinicians and patients around the world.
See Also
- Five stocks we like better than Edwards Lifesciences
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.
